Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically-documented high-risk endometrioid adenocarcinoma with no visible residual disease, defined by the following criteria:~  * Surgical stage I disease with \< 50 myometrial invasion and grade 3 tumor (IAG3) with lymphovascular space involvement;~ * Surgical stage I disease with \>= 50% myometrial invasion and grade 2 or 3 tumor (IBG2, IBG3);~ * Any surgical stage II disease (II);~ * Any surgical stage III disease (IIIA, IIIB, IIIC); and~ * Any surgical stage IV disease with no residual macroscopic tumor~* Surgical staging to include total abdominal hysterectomy, bilateral salpingo-oophorectomy, peritoneal washings, and lymph node samplings as per standard Gynecologic Oncology Group (GOG) criteria~* Eastern Cooperative Oncology Group (ECOG) performance status of \< 2~* Written voluntary informed consent~Exclusion Criteria:~* Serum glutamic oxaloacetic transaminase (SGOT) and/or serum glutamate pyruvate transaminase (SGPT) \> 2.5 times the institutional upper limit of normal~* Total serum bilirubin \> 1.5 mg/dl~* History of chronic or active hepatitis~* Serum creatinine \> 2.0 mg/dl~* Platelets \< 100,000/mm\^3~* Absolute neutrophil count (ANC) \< 1500/mm\^3~* Hemoglobin \< 8.0 g/dl (the patient may be transfused prior to study entry)~* Patient has severe or uncontrolled concurrent medical disease (e.g. uncontrolled diabetes, unstable angina, myocardial infarction within 6 months, congestive heart failure, etc.)~* Patient with any prior chemotherapy or radiotherapy for pelvic malignancy~* Patients with dementia or altered mental status that would prohibit the giving and understanding of informed consent at the time of study entry~* Patients with any history of cancer with the exception of non-melanoma skin cancer are excluded if there is any evidence of other malignancy being present within the past five years

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (paclitaxel, carboplatin, radiation therapy) (Type: EXPERIMENTAL): CHEMOTHERAPY (weeks 1-9, 13-21): Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 3 courses during weeks 1-9 and 3 courses during weeks 13-21.~RADIATION THERAPY (weeks 8-13 or 8-15): Patients with stage I disease undergo HDR brachytherapy once weekly for a total of 5 fractions during weeks 8-13. All other patients undergo EBRT QD 5 days a week for a total of 25 fractions during weeks 8-12 and HDR brachytherapy once weekly for a total of 3 fractions during weeks 13-15.

Based on this trial design, predict the completion outcome and termination type (if applicable).